WO2013032883A3 - Methods of detecting and treating cardiovascular diseases - Google Patents

Methods of detecting and treating cardiovascular diseases Download PDF

Info

Publication number
WO2013032883A3
WO2013032883A3 PCT/US2012/052199 US2012052199W WO2013032883A3 WO 2013032883 A3 WO2013032883 A3 WO 2013032883A3 US 2012052199 W US2012052199 W US 2012052199W WO 2013032883 A3 WO2013032883 A3 WO 2013032883A3
Authority
WO
WIPO (PCT)
Prior art keywords
detecting
methods
cardiovascular diseases
subject
risk
Prior art date
Application number
PCT/US2012/052199
Other languages
French (fr)
Other versions
WO2013032883A2 (en
Inventor
Alexandre Francois Roy STEWART
Naif Ahmad Mahmood ALMONTASHIRI
Robert Roberts
Original Assignee
Ottawa Heart Institute Research Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ottawa Heart Institute Research Corporation filed Critical Ottawa Heart Institute Research Corporation
Publication of WO2013032883A2 publication Critical patent/WO2013032883A2/en
Publication of WO2013032883A3 publication Critical patent/WO2013032883A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/56—IFN-alpha
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Abstract

The invention relates to the use of interferon a-21 for detecting the presence of or increased risk of coronary artery disease in a subject positive for a 9p21 risk allele. Diagnostic methods and kits are provided herein for detecting and reducing the risk of cardiovascular disease, including coronary artery disease, in a subject having the 9p21 risk allele by measuring interferon a-21 in the subject. The invention further relates to therapeutic methods which use interfeuron a-21 level to diagnose and treat cardiovascular diseases.
PCT/US2012/052199 2011-08-26 2012-08-24 Methods of detecting and treating cardiovascular diseases WO2013032883A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161527693P 2011-08-26 2011-08-26
US61/527,693 2011-08-26

Publications (2)

Publication Number Publication Date
WO2013032883A2 WO2013032883A2 (en) 2013-03-07
WO2013032883A3 true WO2013032883A3 (en) 2014-05-22

Family

ID=47757127

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/052199 WO2013032883A2 (en) 2011-08-26 2012-08-24 Methods of detecting and treating cardiovascular diseases

Country Status (1)

Country Link
WO (1) WO2013032883A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3046627B1 (en) 2013-09-18 2019-10-23 The Board of Trustees of the Leland Stanford Junior University Modulation of efferocytosis pathways for treatment of atherosclerotic disease
EP4218812A1 (en) * 2015-02-27 2023-08-02 The Board of Trustees of the Leland Stanford Junior University Combination therapy for treatment of atherosclerosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080299081A1 (en) * 2001-03-30 2008-12-04 Genodyssee Sa Polynucleotides and Polypeptides of the IFNalpha-21 Gene
US20100068705A1 (en) * 2007-02-21 2010-03-18 Decode Genetics Ehf Genetic susceptibility variants associated with cardiovascular disease
US7883851B2 (en) * 2007-05-02 2011-02-08 Board Of Regents, The University Of Texas System Common allele on chromosome 9 associated with coronary heart disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080299081A1 (en) * 2001-03-30 2008-12-04 Genodyssee Sa Polynucleotides and Polypeptides of the IFNalpha-21 Gene
US20100068705A1 (en) * 2007-02-21 2010-03-18 Decode Genetics Ehf Genetic susceptibility variants associated with cardiovascular disease
US7883851B2 (en) * 2007-05-02 2011-02-08 Board Of Regents, The University Of Texas System Common allele on chromosome 9 associated with coronary heart disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HARISMENDY ET AL.: "9p21 DNA variants associated with Coronary Artery Disease impair IFNy signaling response.", NATURE, vol. 470, no. 7333, 10 February 2011 (2011-02-10), pages 264 - 268 *
JARINOVA ET AL.: "Functional Analysis of the Chromosome 9p21.3 Coronary Artery Disease Risk Locus.", ARTERIOSCLER THROMB VASC BIOL., vol. 29, 10 July 2009 (2009-07-10), pages 1671 - 1677 *
PALOMAKI ET AL.: "Association between 9p21 Genomic Markers and Heart Disease.", JAMA, vol. 303, no. 7, 17 February 2010 (2010-02-17), pages 648 - 656 *

Also Published As

Publication number Publication date
WO2013032883A2 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
WO2013192274A3 (en) Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
PH12018501266B1 (en) Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
WO2012149299A3 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
WO2012125872A3 (en) Methods of diagnosing and treating vascular associated maculopathy and symptoms thereof
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2010091049A3 (en) Diagnosis and treatment of cancer
WO2011041582A3 (en) Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
WO2013033609A3 (en) Methods and compositions for the treatment and diagnosis of cancer
ECSP13012776A (en) DUAL VARIABLE DOMAIN IMMUNOGLOBULINS
WO2012109466A3 (en) Long non-coding rna spry4-it1 as a diagnostic and therapeutic agent
WO2011092285A3 (en) Means and methods for diagnosing heart failure in a subject
WO2009137807A3 (en) Compositions and methods related to mirna modulation of neovascularization or angiogenesis
WO2012083132A3 (en) Diagnosis and treatments relating to th2 inhibition
EA201491151A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
EP2667237A4 (en) Equipment and method for examining, diagnosing or aiding the diagnosis, and therapy of functional vision problems
EP2723866A4 (en) Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
MX2013001906A (en) Methods of reducing blood lactate concentration.
HK1215173A1 (en) Methods of treating s. aureus-associated diseases
WO2012017430A3 (en) Microrna patterns for the diagnosis, prognosis and treatment of melanoma
WO2017027391A3 (en) Genetic abnormalities in plasma cell dyscrasias
WO2013090635A3 (en) Composition and method for the diagnosis and treatment of iron-related disorders
WO2015081283A3 (en) Long non-coding rna as a diagnostic and therapeutic agent
EA201190312A1 (en) SUBSTITUTED PIPERIDINES
CA2851761C (en) Method of diagnosis, prognostic or treatment of neurodegenerative diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12827629

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12827629

Country of ref document: EP

Kind code of ref document: A2